4D Molecular Therapeutics Inc. - notizie pubblicate 191 - letture 5.405
4D MOLECULAR THERAPEUTICS INC.
Initial Registration Statement for Employee Benefit Plan - Form S-8
As filed with the securities and exchange commission on march 15, 2023 registration no. 333- united states securities and exchange commission washington, d.c. 20549 form s-8 regist ...
4D MOLECULAR THERAPEUTICS INC.
4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
Provided updates on clinical pipeline, including 4d-150 forwet age-related macular degeneration (wet amd) and diabetic macular edema (dme), 4d-710 for cystic fibrosis lung disease, ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
4D-310 INGLAXA Phase 1/2 Interim Clinical Data Presentation – February 2023
Update from inglaxa phase 1/2 clinical trials development plans for 4d-310 genetic medicine for fabry disease cardiomyopathy february 22, 2023 legal disclaimer this presentation co ...
4D MOLECULAR THERAPEUTICS INC.
4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer 4d molecular therape ...
4D MOLECULAR THERAPEUTICS INC.
4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer 4d molecular therape ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer 4d molecular therape ...
4D MOLECULAR THERAPEUTICS INC.
Current Report - Form 8-K
8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of r ...
4D MOLECULAR THERAPEUTICS INC.
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema
4d-150 phase 2 spectra clinical trialfor diabetic macular edema enrollment is expected to initiate in q3 2023 initial phase 1 prism clinical trial with 4d-150 for wet age-related m ...
4D MOLECULAR THERAPEUTICS INC.
Current Report - Form 8-K
8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of r ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti